Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

Dosyalar

Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients Experience from anEarly Access Program in Turkey.pdf (419.92 KB)

Tarih

Yazarlar

Cinkir, H. Yesil

Cilt

14

Sayı

10
S

URI

https://hdl.handle.net/11443/2813
http://dx.doi.org/10.1016/j.jtho.2019.08.1166

Koleksiyonlar

Tam öğe sayfası